Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, and Crown CRO, a contract research organization based in Finland, today announced Crown’s engagement to manage Adial’s Phase 3 clinical trial for AD04 for the treatment of alcohol use disorder (AUD). The FDA approved protocol for this Phase 3 clinical trial is a 24-week trial with 290 patients in 30 clinical sites in 5 European countries.
The expanding landscape of Immuno-Oncology – benefits and challenges
I am sure we all have been or will be […]
Crown CRO’s second CRA training successfully completed
Last year, Crown CRO launched a CRA training program that […]
Rescuing a clinical study that has lost one or more of its wheels
An over 30-year long career within clinical research and development […]
The best way to empower girls is through education
Every year on the 11th of October, the International Day […]
Crown CRO supports international students by offering mentoring to those interested in Clinical Research
The University of Helsinki has started a mentoring program (HelsinkiUNI […]